Main Article Content
The Covid-19 virus disease has been shown to affect numerous organs and systems including the liver. The study aimed to compare lipid profiles and liver enzyme levels in individuals who had recovered from Covid-19 infection. To achieve the study objectives, liver Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Alkaline phosphatase (ALP), Random Blood Sugar (RBS) and Lipid profile which include cholesterol, High-Density Lipoprotein (HDL), Triglycerides (T.G), Low-Density Lipoprotein (LDL), and Very low-density Lipoprotein (VLDL) were determined.
One hundred twenty serum samples were obtained, of which fifty samples were utilized as the control healthy persons (not affected by COVID) and seventy samples came from COVID-19 patients who had recovered. Liver enzymes showed a significant increase in serum AST, ALT, and ALP between the two groups (p-values) of 0.001. The lipid profile demonstrated notable ariations which showed an increase in cholesterol, TG, LDL, and VLDL., as well as a decrease in HDL level in the recovered patients’ group compared to the control (p-values) with a value of 0.001. There were no significant differences in RBS between the recovered patients’ group as compared with the control, (p-value) (0.062). Also, body mass index )BMI( and age showed no significant differences. This study concluded that Covid 19 survivors experienced issues with their lipid profiles and liver enzymes
This work is licensed under a Creative Commons Attribution 4.0 International License.
Mohammed SK, Taha MM, Taha EM, Mohammad MNA. Cluster Analysis of Biochemical Markers as Predictor of COVID-19 Severity. Baghdad Sci J. 2022, 19(6): 1423-1429. https://doi.org/10.21123/bsj.2022.7454.
Yunus AA, Yunus AA, Ibrahim MS, Ismail S. Future of Mathematical Modelling: A Review of COVID-19 Infected Cases Using SIR Model. Baghdad Sci J. 2021: 18(1): 824-9. https://doi.org/10.21123/bsj.2021.18.1(Suppl.).0824
Chan JF-W, To KK-W, Tse H, Jin D-Y, Yuen K-Y. Interspecies transmission and emergence of novel viruses: lessons from bats and birds. Trends Microbiol; 2013; 21(10): 544–555 . http://dx.doi.org/10.1016/j.tim.2013.05.0.
Cascella M, Rajnik M, Aleem A, Dulebohn SC, Di Napoli R. Features, evaluation, and treatment of coronavirus (COVID-19). StatPearls. 2022: 1–93. http://creativecommons.org/licenses/by-nc-nd/4.0/.
Sahu KK, Siddiqui AD. From Hematologistʼs desk: The effect of COVID‐19 on the blood system. Am J Hematol. 2020; 95(8): E213–E215. https://doi.org/10.1002/ajh.25849
FAn BE. Hematologic parameters in patients with COVID-19 infection: a reply. Am J Hematol. 2020; 95(8): E215–E215. https://doi.org/10.1002 / ajh.25847
Zhang C, Shi L, Wang F-S. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol; 2020;5(5): 428–430. https://doi.org/10.1016/S2468-1253(20)30057-1.
Chau T, Lee K, Yao H, Tsang T, Chow T, Yeung Y, et al. SARS‐associated viral hepatitis caused by a novel coronavirus: report of three cases. Hepatology; 2004; 39(2): 302–310. https://doi.org/10.1002/hep.20111.
Alsaad KO, Hajeer AH, Al Balwi M, Al Moaiqel M, Al Oudah N, Al Ajlan A, et al. Histopathology of Middle East respiratory syndrome coronovirus (MERS‐CoV) infection–clinicopathological and ultrastructural study. Histopathology. 2018; 72(3): 516–524. https://doi.org/10.1111/his.13379.
Hwaiz R, Merza M, Hamad B, HamaSalih S, Mohammed M, Hama H. Evaluation of hepatic enzymes activities in COVID-19 patients. Int Immunopharmacol. 2021; 97: 1567-5769 https://doi.org/10.1016/j.intimp.2021.107701.
Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The lancet. 2020; 395(10223): 507–513 https://doi.org/10.1016/S0140-6736(20)30211-7.
Yang X, Yu Y, Xu J, Shu H, Liu H, Wu Y, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020; 8(5): 475–481. https://doi.org/10.1016/S2213-2600(20)30079-5.
Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Covid-19 in China. N Engl J Med. 2020; 382(18): 1708-1720. https://doi.org/10.1056/NEJMoa2002032.
Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003; 426(6965): 450–454. https://doi.org/10.1038/nature02145.
Kareem AM, Al-Azzawi SN. Comparison Between Deterministic and Stochastic Model for Interaction (COVID-19) With Host Cells in Humans. . Baghdad Sci J. 2022; 19(5): 1140. http://dx.doi.org/10.21123/bsj.2022.6111
Chai X, Hu L, Zhang Y, Han W, Lu Z, Ke A, et al. Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection. bioRxiv. 2020; 1–13. https://doi.org/10.1101/2020.02.03.931766
Jothimani D, Venugopal R, Abedin MF, Kaliamoorthy I, Rela M. COVID-19 and the liver. J Hepatol. 2020;73(5): 1231–1240. https://doi.org/10.1016/j.jhep.2020.06.006.
Wilson J M, Lee J, Shook N J. COVID-19 worries and mental health: the moderating effect of age. Epub. 2021; 25(7): 1289-1296. https://doi.org/10.1080/13607863.2020.1856778
Shah H, Khan MSH, Dhurandhar N V, Hegde V. The triumvirate: why hypertension, obesity, and diabetes are risk factors for adverse effects in patients with COVID-19. Acta Diabetol. 2021; 58(7): 831–843 . https://doi.org/10.1007/s00592-020-01636-z.
Chu Y, Yang J, Shi J, Zhang P, Wang X. Obesity is associated with increased severity of disease in COVID-19 pneumonia: a systematic review and meta-analysis. Eur J Med Res. 2020; 25(1): 1–15. https://doi.org/10.1186/s40001-020-00464-9.
Salve A, Gajghate A, Ansari S, Malik R, Uike S, Khetal N. Evaluation of blood glucose levels of COVID-19 patients before and after recovery regardless of their diabetic status. J Datta Meghe Inst Med Sci Univ 2022;17 (1):43-6
Wijarnpreecha K, Ungprasert P, Panjawatanan P, Harnois DM, Zaver HB, Ahmed A, et al. COVID-19 and liver injury: a meta-analysis. Eur J Gastroenterol Hepatol. 2021; 33(7): 990–995 https://doi.org/10.1097/MEG.0000000000001817
Del Zompo F, De Siena M, Ianiro G, Gasbarrini A, Pompili M, Ponziani FR. Prevalence of liver injury and correlation with clinical outcomes in patients with COVID-19: systematic review with meta-analysis. Eur Rev Med Pharmacol Sci. 2020 ; 24(24): 13072–13088 . https://search.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resource/es/covidwho-1000854
Zarei M, Bose D, Nouri‐Vaskeh M, Tajiknia V, Zand R, Ghasemi M. Long‐term side effects and lingering symptoms post COVID‐19 recovery. Rev Med Virol. 2022; 32(3): 2289 https://doi.org/10.1002/rmv.2289.
Nazzal AG, Sabbar AG. Evaluation of liver function (GPT, GOT, ALP) and cardiac isoenzyme (LDH1, LDH2, LDH3, LDH4) in COVID19 patients after recovering. 2022; 4(1): 68–80. https://www.iasj.net/iasj/download/5c8646c8cc37f1d3
Wu QI, Zhou L, Sun X, Yan Z, Hu C, Wu J, et al. Altered lipid metabolism in recovered SARS patients twelve years after infection. Sci Rep. 2017; 7(1): 1–12. https://doi.org/10.1038/s41598-017-09536-z.
Roccaforte V, Daves M, Lippi G, Spreafico M, Bonato C. Altered lipid profile in patients with COVID-19 infection. J Lab Precis Med. 2021; 6(2): 1–8 http://dx.doi.org/10.21037/jlpm-20-98.
Feingold K R. Lipid and lipoprotein levels in patients with COVID-19 infections. MDText. 2020; 11(26): 1 –30. https://www.altmetric.com/details/95717021.
Fijen L M, Grefhorst A, Levels J H, Cohn D M. Severe acquired hypertriglyceridemia following COVID-19. Case Rep. 2021; 14(11): e246698. http://dx.doi.org/10.1136/bcr-2021-246698.